FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

Cloud computing banner background for smart city

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

First-of-its-kind brain surgery simulator appears to be a feasible approach for training neurosurgeons

Previous article

The role of bacteria in cancer growth

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News